Acta Pharm Sin B 11 , 24492468
Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Noren GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh N, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C
5 In addition to approved indications, GLP-1 agonists may have a role in the management of cutaneous disease, as demonstrated through off-label treatment in the literature (Table 1)
When to Talk to Your Doctor (And What to Ask) If youve followed these steps for 3 months and still see minimal weight loss, schedule a specialist visit
| The obesity-MS connection | Emerging research on semaglutide and MS | How does Wegovy work
doi: 10.1159/000053170 3 Albertsson-WiklandKRosbergSKarlbergJGrothT